Thursday, February 9, 2012

FDA Warning on Long Term Proton Pump Inhibitor Drugs

Proton pump inhibitors are very powerful inhibitor of acid secretion in stomach and can lower the acidity (PH) inside stomach to a great extent.
The patients of gastroesophageal reflux (GERD) disease, almost get addicted to this drug because it gives them relief from considerable discomfort, the heart burn or burning sensation inside the chest with reflux of contents of stomach.
But, continuous use of it can land the person in a lot of problem as acid in stomach can not kill the invading microbes; for which it is meant for.
The FDA warned today (08.02.2012) that use of proton pump inhibitors (PPIs) may increase the risk of Clostridium difficile associated diarrhoea, a hard to treat diarrhoeal condition.

Deutsch: Clostridium difficile angereichert au...
Image via Wikipedia; C. difficile
Taking broad spectrum antibiotics can kill the friendly bacteria present in the gut micro-flora to dis-balance the normal micro-environment. Broad spectrum antibiotics and PPI combination may cause havoc in the gut micro-flora.
The FDA advised healthcare providers to consider a diagnosis of C. difficile-associated diarrhoea if patients taking PPIs present with diarrhoea that is not improving and said patients should take the lowest dose of PPI for the shortest time possible to improve the condition being treated.
The agency is working with the drug makers to modify the labels to include the possible risk of C. difficile-associated diarrhoea.
The warning applies to the following PPIs, both prescription and over-the-counter:
  • rabeprazole sodium
  • dexlansoprazole
  • esomeprazole magnesium
  • omeprazole
  • lansoprazole
  • pantoprazole
PPIs have been associated with other adverse events in the past, including resistance to clopidogrel (Blood thinning agent), low magnesium levels resulting in a greater risk of leg spasms, arrhythmias (Irregularity in heart beat), and seizures; greater risk of osteoporotic fractures (Thinned bone) from chronic use; and cardiac birth defects when used during pregnancy.
The FDA is also reviewing the possible risk of in C. difficile-associated diarrhea in users of another class of acid suppressing medications, the histamine H2 receptor blockers.

Enhanced by Zemanta


Get my updates delivered into your inbox; Privacy Policy :

Click here to Subscribe news feed from "Clinicianonnet; so that you do not miss out anything that can be valuable to you !!


Related Posts Plugin for WordPress, Blogger...